• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Mesenchymal Stem Cells - Global Strategic Business Report Product Image

Mesenchymal Stem Cells - Global Strategic Business Report

  • ID: 2769226
  • January 2014
  • Region: Global
  • 179 Pages
  • Global Industry Analysts, Inc

This report analyzes the worldwide markets for Mesenchymal Stem Cells (MSCs) in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2018. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 51 companies including many key and niche players such as:

- Aastrom Biosciences, Inc.
- Cell Applications, Inc.
- Celprogen, Inc.
- Cyagen Biosciences Inc.
- EMD Millipore Corporation
- Genlantis, Inc.

Note: Product cover images may vary from those shown

MESENCHYMAL STEM CELLS

MCP-7815 A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Mesenchymal Stem Cells - The Next Big Leap in Medicine
Current and Future Analysis
The Present and Future of MSC Therapies
Table 1: Percentage Share Breakdown of Mesenchymal Stem Cells (MSCs) Clinical Trials by Region (2013) (includes corresponding Graph/Chart)
Mesenchymal Stem cell Therapies: A List of Select Pipeline Products (as of December 2013)
Widespread Commercialization of 'Off-the-Shelf' MSCs to Become a Reality
Software Companies Endeavour to Cash in on the Boom

2. MARKET DRIVERS, TRENDS & ISSUES
Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies
Table 2: Global Population Statistics for the 65+ Age Group (2013E) (includes corresponding Graph/Chart)
Adult Stem Cells Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research
Adult Stem Cells and Embryonic Stem Cells - A Comparison
MSCs versus Embryonic or Induced Pluripotent Stem Cells
MSC Therapies Immune to Ethical Issues Applicable to Embryonic Stem Cells
MSCs - A Potential Vehicle for 'Targeted Drug Delivery'
Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements
Major Challenges Confronting Mesenchymal Stem Cell Market

3. STEM CELL MARKET - A MACRO PERSPECTIVE
Mesenchymal Stem Cells Dominate
Stem Cell Research in Top Gear
Table 3: Global Stem Cell Usage in Research (2013): Percentage Share Breakdown by Type (includes corresponding Graph/Chart)
Table 4: Percentage Share Breakdown of Stem Cell Clinical Trials by Country (2012) (includes corresponding Graph/Chart)
Major Achievements Thus Far
A Glimpse of Major Historical Events in the Area of Stem Cell Research
Laws Governing Stem Cells Research - A Regulatory Overview
Laws and Regulations in Stem Cells Research in Select Countries
Market Dynamics and Trends
North America Dominates Global Stem Cells Research
Table 5: World 10-Year Perspective for Adult Stem Cell Research by Geographic Region - Percentage Breakdown of Annual Investments for US, Europe and Rest of World Markets for Years 2008, 2011 & 2017 (includes corresponding Graph/Chart)
Stem Cell Therapy Continues to Traverse from Concept to Reality
Stem Cells Bode Tremendous Potential in Medicine
Long Wait Imperative for Stem Cell Therapies
Korea Debuts the World's First Somatic Stem Cell Based Therapy
Key Restraints for Stem Cell Market
Ethical Issues
Insurance Coverage
Stem Cell Tourism - A Boon or Bane?
Government Regulations Fail to Prevent Rise in Stem Cell Tourism
Teratomas - No Longer an Impediment to Stem Cell Therapy Development
US and Japan Surge Ahead of Europe in Stem Cell Patents
Table 6: Global Stem Cells Patent Analysis by Market (2010): Percentage Breakdown of Number of Patents Issued for US, Japan and Europe (includes corresponding Graph/Chart)
Table 7: Global Stem Cells Patent Analysis by Product (2010): Percentage Breakdown of Number of Patents Issued for Adult Stem Cells, Human Embryonic Stem Cells, Mesenchymal Stem Cells, Hematopoietic Stem Cells, Neuronal Stem Cells and Others (includes corresponding Graph/Chart)
Table 8: Leading Stem Cell Companies by Patents (2010): Percentage Breakdown of Number of Patents Secured for Geron Corp., Osiris Therapeutics, Olympus Corporation, Wisconsin Alumni Research Foundation, Kourion Therapeutics AG, Japan Science & Tech Agency and Others (includes corresponding Graph/Chart)
Issues Hold Back Development of Stem Cell Therapies
Advantages and Drawbacks of Various Stem Cells

4. REVIEW OF SELECT MAJOR STEM CELL VARIANTS
Adult Stem Cells
A Low Risk Investment
Adult Stem Cells Garner More Investments for Research
Low Versatility - A Major Limiting Factor of Adult Stem Cells
Hematopoietic Stem Cells - Enjoying Enduring Success
Restraining Factors
Induced Pluripotent Stem Cells - An Alternative to ESCs
A Peek into the Discovery of iPS
Drug Development - A Major Application for iPS
Use of iPS for Regenerative Medicine
Establishing iPS Cell Banks
Intractable and Congenital Disease Treatments
Embryonic Stem Cells to Transfigure Medicine
Ethical Issues and Technical Hurdles Bog Down hESC Research
Lack of Safety and Efficacy Data - A Key Concern

5. MESENCHYMAL STEM CELL RESEARCH BY APPLICATION
Mesenchymal Stem Cells in Orthopedics
MSC based Models for Orthopedic Repair
Delivery of MSCs to Regions Requiring Therapy
MSCs in the Treatment of Osteoarthritis
MSCs in the Treatment of Rheumatoid Arthritis
MSCs in Cancer Treatment
MSCs in Hepatology
MSCs in Neurology
MSCs in Cardiology
MSCs in Radiotherapy
MSCs in the Treatment of Diabetes
MSCs in the Treatment of Autoimmune Diseases
MSCs in Treatment of Premature Ovarian Failure
MSCs for Gene Therapy
MSC Therapy in the Treatment of Lung Diseases
MSCs in Colon Repair
MSCs in Kidney Repair

6. PRODUCT OVERVIEW
Mesenchymal Stem Cells (MSCs) - An Introduction
History
What Are Allogeneic Mesenchymal Stem Cells?
Why Are MSCs So Popular?
Some Major Sources of Mesenchymal Stem Cells
Bone Marrow
Wharton's Jelly and Umbilical Cord Blood
Adipose Tissue
Trophoblastic Tissues
Amniotic Fluid
Developing Tooth Bud of Mandibular Third Molar
Mechanism of Mesenchymal Stem Cell Therapy
Important Features of Mesenchymal Stem Cells
Morphology
Identification/Detection
Differentiation Capacity
Immuno-modulatory Effects
Culturing
Clinical Use
Production of Clinical-Grade MSCs
Drawbacks of MSCs

7. PRODUCT INNOVATIONS/LAUNCHES
Vitro Biopharma Unveils New Range of Stem Cell Products
Rainbow Scientific Launches Biological Industries' Stem Cell Culture Systems
LABS Unveils New Laboratory Test for Screening Biologic Products
Vitro Diagnostics Launches New Range of Products
IntelliCell BioSciences Develops Stromal Vascular Fraction Cells from Non-living Adipose Tissues
Vitro Diagnostics Unveils New Products for Cell Therapy
Vitro Diagnostics Launches Multiple Stem Cell Products

8. RECENT INDUSTRY ACTIVITY
Life Technologies Inks License and Collaborative Stem Cell Research Agreement with Harvard University
Stemedica Cell Technologies and Life Technologies Ink Global Distribution Agreement
Stemedica Asia and Kalbe's Stem Cell and Cancer Institute Ink Definitive Licensing Agreement
ThermoGenesis Divests ThermoLine Assets to Helmer Scientific
ThermoGenesis Inks Definitive Merger Agreement with TotiRx
ThermoGenesis Obtains Registration Approval or AXP® AutoXpress® in China
Athersys Receives MHRA Approval for the Expansion of Phase 2 Clinical Trial of MultiStem Cell Therapy in Ischemic Stroke
Osiris Therapeutics Receives Orphan Drug Designation for Prochymal® from EMA
Stemedica Commences Phase II Stroke Trial for Stemedyne-MSC
RNL Bio Undergoes Name Change to K-STECMCELL
Mesoblast Secures US FDA Approval to Manufacture MSCs in Singapore
Fibrocell Science and UCLA Ink Exclusive Agreement
Stemedica Enters into an Agreement with Scripps Research Institute
GE Healthcare Inks Licensing Agreement with Cellular Dynamics International
GE Healthcare and BGI Ink Multi-year Research Collaboration Agreement
Osiris Therapeutics Reacquires Rights to Chondrogen and Prochymal from Genzyme
Vitro BioPharma Enters into Distribution Agreement with StemGenesis
ThermoGenesis and Golden Meditech Ink Product Purchase and Distribution Agreement
Vitro Biopharma Announces Expansion of Partnership with Neuromics
Cryo-Save Enters into Collaboration with Policlinico "Gemelli" University Hospital
Cryosite Enters into Collaboration with Regeneus
Fibrocell and UCLA Discover Rare Adult Stem Cell Subtypes
Mesoblast Receives Approval for Phase II Type 2 Diabetes Study
Athersys Receives US Patent for MultiStem in the Treatment of GvHD
Stemedica Receives FDA Approval for Phase II Clinical Trial of Ischemia Tolerant MSCs
Fast Forward and Athersys Sign Sponsored Research Agreement
ScreenCell® Inks Global Collaboration and Distribution Agreement with Transgenomic
Mesoblast Enters into Partnership with Lonza Group
China Sky One Medical to Inaugurate Harbin Tian Xin Biological Engineering
MedRebels Succeeds in Reducing Inflammation in Knee Joints by Injecting Bone Marrow Stem Cells
RenovoCyte Inks Partnership Agreement with VetCell
Mesoblast Performs First Minimally Invasive Procedure for Lumbar Disc Repair in Phase II Clinical Trials of MPC Product
AlloSource Inks Licensing Agreement with NuVasive
Cephalon Inks Strategic Alliance with Mesoblast
Aastrom and ATEK Medical Ink Manufacturing and Development Partnership
Osiris Therapeutics Obtains FDA Orphan Drug Designation for Stem Cell Product for Type 1 Diabetes

9. FOCUS ON SELECT PLAYERS
Aastrom Biosciences, Inc. (US)
Cell Applications, Inc (US)
Celprogen, Inc (US)
Cyagen Biosciences Inc (US)
EMD Millipore Corporation (US)
Genlantis, Inc. (US)
Life Technologies Corporation (US)
Lonza Group (Switzerland)
Mesoblast Limited (Australia)
Neuromics (US)
Osiris Therapeutics, Inc. (US)
Orthofix International N.V. (Curacao)
PromoCell GmbH (Germany)
R&D Systems, Inc (US)
ScienCell Research Laboratories (US)
Stemcell Technologies Inc (Canada)
Stemedica Cell Technologies, Inc. (US)
StemGenesis (US)
Trevigen, Inc. (US)
Vitro Biopharma (US)

10. GLOBAL MARKET PERSPECTIVE
Table 9: Global Recent Past, Current & Future Analysis for Mesenchymal Stem Cells by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 Through 2018 (includes corresponding Graph/Chart)
Table 10: World 10-Year Perspective for Mesenchymal Stem Cells by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2009, 2013 & 2018 (includes corresponding Graph/Chart)

III. MARKET
1. THE UNITED STATES
A.Market Analysis
Current and Future Analysis
Rapidly Ageing Population: A Major Driving Demand for MSC based Therapies
Table 11: North American Elderly Population by Age Group (1975-2050) (includes corresponding Graph/Chart)
Overview of the US Stem Cells Market
Rising Governmental Investments in Stem Cell Therapies - A Growth Booster
FDA Issues Warning Against Illegal Stem Cell Therapies
US Regulates Stem Cells as Drugs
Federal Law on Stem Cells in the US
NIH at the Forefront of Research Funding
NIH Guidelines on Stem Cell Research Funding
Bans and Restrictions on Stem Cell Research
American Type Culture Collection Inc (ATCC) - A Major Non
Profit Organization
Product Launches
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 12: US Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

2. CANADA
A.Market Analysis
Current and Future Analysis
Stem Cell Regulations
Stemcell Technologies Inc - A Key Player
B.Market Analytics
Table 13: Canadian Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

3. JAPAN
A.Market Analysis
Current and Future Analysis
New Regulation for Accelerated Stem Cell Approval and Its Impact on Stem Cells Product Market
B.Market Analytics
Table 14: Japanese Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

4. EUROPE
A.Market Analysis
Current and Future Analysis
Ageing Population to Drive Demand for MSC based Therapies
Table 15: Population Breakup by Age Group for Select European Countries: 2012 (as a Percentage of Total Population) (includes corresponding Graph/Chart)
Legislations on Stem Cell Research and Therapy in the EU
Unproven Stem Cell Therapies Receive Government Backing in the EU?
Scientists and Government Tussle over Safety of Stamina Foundation's MSC Therapy in Italy
Stem Cell Clinics Shut Down in Germany due to Malpractices
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 16: European Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC
A.Market Analysis
Current and Future Analysis
Overview of Select Countries
Australia
Stem Cell Tourism - A Popular Trend in Australia
South Korea
South Korea Pacing towards Regaining Lost Glory in Stem Cell Research
South Korea Upbeat on Stem Cell Therapy Market Potential
India
An Outline of the Stem Cell Research Structure in India
Table 17: Indian Adult Stem Cell Research (2012): Percentage Share Breakdown by Type (includes corresponding Graph/Chart)
A Regulatory Picture of the Indian Stem Cell Research and Therapy
Adult Stem Cells - A Highly Money-Spinning Market
Indians 'Bank' on Dental Stem Cells
New Zealand
Stem Cell Research Scenario in New Zealand
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 18: Asia-Pacific Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

6. REST OF WORLD
A.Market Analysis
Current and Future Analysis
Stem Cell Research in Full Swing in Israel
Key Players
B.Market Analytics
Table 19: Rest of World Recent Past, Current and Future Analysis for Mesenchymal Stem Cells Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 51 (including Divisions/Subsidiaries - 51)
The United States (32)
Canada (1)
Europe (7) - Germany (2) - The United Kingdom (1) - Rest of Europe (4)
Asia-Pacific (Excluding Japan) (9)
Latin America (1)
Middle East (1)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos